Murrell DF, Patsatsi A, Stavropoulos P, Baum S, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton
tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. Br J Dermatol 2021;185:745-755.
PMID: 33942286